Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRALULALA-AZI azithromycin prevention trial in children with structural lung disease
2024-518730-88-00Phase 4Authorised
- Sponsor
- Rigshospitalet
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in bronchiectasis, bronchopulmonary dysplasia (BPD), tracheobronchomalacia (TBM) and 4 more comparing Azithromycin maintenance therapy with Placebo comparator (2 arms). Primary endpoint: Number of respiratory exacerbations. Planned start Jul 2026; status: authorised.
02
Drugs
azithromycin
03
Conditions
bronchiectasisbronchopulmonary dysplasia (BPD)tracheobronchomalacia (TBM)congenital bronchopulmonary malformation (CBPM)chronic atelectasis
Beyond the preview
Go deeper on 2024-518730-88-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518730-88-00.